Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 3;105(12):1591–1600. doi: 10.1111/cas.12556

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Fig. 2 — Correlation of the immunostained expression of each RTK with other RTKs, and RTK expression pattern of recurrent tumors. (a) Individual RTKs were immunohistochemically stained and their staining level in the same tumor was correlated with that of the other RTKs. HER3 expression was closely correlated with that of IGF-1R (P < 0.0001, R = 0.41), and EphA2 (P < 0.0001, R = 0.34). (b) The tumors of the 53 patients who recurred were immunohistochemically analyzed for RTK expression; 40 patients (75.5%) were HER3-positive, 39 patients (73.6%) were EGFR-positive, two patients (3.8%) were HER2-positive, 36 patients (67.9%) were IGF-1R-positive, and 27 patients (50.9%) were EphA2-receptor positive. Of the RTKs expressed, HER3 overexpression showed the highest association with recurrence.